Rapport Therapeutics Inc RAPP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $35.21
- Day Range
- $34.10–36.18
- 52-Week Range
- $10.58–42.15
- Bid/Ask
- $35.84 / $35.98
- Shares Outstanding
- 47.83M
- Market Cap
- $1.71B
- Volume/Avg
- 593,263 / 312,706
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 75.13
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 84
- Website
- https://www.rapportrx.com
Valuation
|
Metric
|
RAPP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.63 |
Price/Sales | 75.13 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RAPP
|
|---|---|
Quick Ratio | 26.64 |
Current Ratio | 27.08 |
Interest Coverage | — |
Quick Ratio
RAPP
Profitability
|
Metric
|
RAPP
|
|---|---|
Return on Assets (Normalized) | −20.04% |
Return on Equity (Normalized) | −21.19% |
Return on Invested Capital (Normalized) | −24.25% |
Return on Assets
RAPP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Hjwczqk | Bcbwgp | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vbclfmgx | Mggxn | $63B | |||
| argenx SE ADR
ARGX
| Zrzrrbgn | Yhlzk | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mgyqszbcd | Xzhvk | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Pgdprhdcp | Pmvwq | $24B | |||
| BioNTech SE ADR
BNTX
| Bnmgmkws | Lws | $22B | |||
| Incyte Corp
INCY
| Hqgnbsf | Wcdw | $21B | |||
| Moderna Inc
MRNA
| Jwtnbhydw | Szltt | $18B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Zqcbycdp | Stswv | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Fvtwwlk | Svh | $13B |
United States